GlassScriptPhysician profile
Madelyn L Eudy
NPI 1578103636
$10,905.70
in general payments reported to CMS, 2019-2025
68 companies · $671 in 2025
The $671 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,982 · 2022: $3,501 · 2023: $2,387 · 2024: $1,365 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.29 |
| Education | $185.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,832.45 | 2021-2025 | |
| Novo Nordisk INC | $741.45 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $551.25 | 2021-2025 | Mounjaro, Jardiance, Taltz |
| Astrazeneca Pharmaceuticals LP | $493.72 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Bausch Health US, LLC | $484.63 | 2021-2023 | Aplenzin, Wellbutrin |
| Biohaven Pharmaceutical Holding Company LTD. | $343.42 | 2022 | |
| Amgen INC. | $320.80 | 2021-2025 | Otezla, Otezla, Repatha |
| Pfizer INC. | $313.76 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $309.11 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.41 | 2021-2024 | Jardiance, Synjardy |
| Biohaven Pharmaceuticals, INC. | $285.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.27 | 2021-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $268.89 | 2021-2023 | Verquvo, Belsomra, Lagevrio |
| Novartis Pharmaceuticals Corporation | $253.44 | 2021-2025 | Leqvio, Entresto |
| Takeda Pharmaceuticals U.S.A., INC. | $244.77 | 2021-2023 | Trintellix |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelyn Eudy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.